2025-2034 Visceral Pain Market Evolution: Disruptions, Innovations, and Untapped Opportunities

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Visceral Pain Market Through 2025?
The market encompassing visceral pain treatments has experienced robust expansion recently, projected to see its valuation increase from $13.84 billion in 2024 to $14.82 billion the following year, reflecting a calculated compound annual growth rate of 7.1%; this historical upward trajectory is fueled by several factors, notably the demographic shift toward older age groups, a higher prevalence of long-term illnesses, significant developments in medical science, the scaling up of health service facilities, and greater public understanding coupled with more frequent detection of these conditions.

What's the Projected Size of the Global Visceral Pain Market by 2029?
Growth projections for the visceral pain sector indicate robust expansion ahead, with the market poised to a valuation of $18.58 billion by 2029, driven by a compound annual growth rate (CAGR) calculated at 5.8%. This anticipated expansion throughout the forecasting tenure is fueled by several factors, notably advancements in pain management technology, escalating consumer preference for methods that avoid surgery, unexplored avenues and developing regions, customized treatment paradigms, and the incorporation of digital healthcare platforms. Key developments shaping this period feature a movement toward employing several pain management modalities concurrently, heightened focus on non-traditional therapeutic approaches, the proliferation of treatments designed for particular pain conditions, the evolving significance of remote consultation in managing discomfort, and the embedding of artificial intelligence within pain evaluation processes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/visceral-pain-global-market-report

Top Growth Drivers in the Visceral Pain Industry: What's Accelerating the Market?
Anticipated increases in the need for pain-relieving drugs are projected to stimulate the expansion of the visceral pain sector in the future. Analgesics are defined as pharmaceutical agents that lessen discomfort by reducing or entirely stopping the brain's recognition of pain impulses. These medications assist in controlling visceral pain through intervention with the nervous system, thereby modifying the pain messages originating from the body's internal structures. As an illustration, data from the New England Journal of Medicine, a UK medical periodical released weekly, indicated that by December 2023, more than 53,600 healthcare professionals were administering buprenorphine, a rise of 11,500 prescribers when contrasted with the figures from December 2022. Consequently, this escalating requirement for analgesics is the force propelling the visceral pain market's development.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13950&type=smp

What Trends Will Shape the Visceral Pain Market Through 2029 and Beyond?
Leading enterprises within the visceral pain sector are actively innovating, bringing forth novel offerings like NHE3 Inhibitors, with the goal of delivering dependable solutions to the consumer base. These NHE3 inhibitors constitute a category of pharmaceuticals designed to achieve therapeutic effects through the blockage of the Sodium-Proton-Exchanger subtype 3 (NHE3) within the gastrointestinal tract. Specifically, in the month of April in 2022, Ardelyx, a US-based entity specializing in biopharmaceuticals, introduced an NHE3 Inhibitor medication named IBSRELA. IBSRELA marks a groundbreaking therapeutic option for mature individuals afflicted by irritable bowel syndrome accompanied by constipation (IBS-C), functioning by impeding the Sodium-Hydrogen Exchanger 3 (NHE3) located in both the small bowel and the colon; preclinical investigations suggest this mechanism contributes to the amelioration of abdominal discomfort by lowering both visceral hypersensitivity and the gut's permeability.

What Are the Main Segments in the Visceral Pain Market?
The visceral painmarket covered in this report is segmented -

1) By Drug Class: Calcium Channel Blockers; Nonsteroidal Anti-Inflammatory (NSAID); Other Drug Classes
2) By Indications: Interstitial Cystitis; Crohn's; Irritable Bowel; Chronic Prostatitis; Other Indications
3) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:
1) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAID): Selective COX-2 Inhibitors; Non-Selective NSAIDs
3) By Other Drug Classes: Opioids; Tricyclic Antidepressants (TCAs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13950&type=smp

Which Top Companies are Driving Growth in the Visceral Pain Market?
Major companies operating in the visceral pain market report are Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Endo International PLC, Grünenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.

Which Regions Will Dominate the Visceral Pain Market Through 2029?
North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13950

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.